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TO THE EDITOR
Bowenoid papulosis (BP) is a disease
characterized by multiple brown-to-
black papules on the genitalia and
histological changes similar to Bowen’s
disease, ranging from low to severe
dysplasia. The high-risk, oncogenic hu-
man papillomavirus (HPV) type 16 has
been found in most cases of BP (Porter
et al., 2002; Gross and Pfister, 2004).
Several studies have shown that the
transition of intraepithelial precursor
lesions to carcinoma (in situ) is asso-
ciated with integration of the virus into
the cellular genome (Zur Hausen, 2002;
Hopman et al., 2004). In situ hybridiza-
tion can efficiently identify the physical
status of HPV in tissue cells, as punctate
and diffuse nuclear signals correlate
with restriction digestion and Southern
blot hybridization results to detect inte-
grated or replicative (episomal) HPV,
respectively (Cooper et al., 1991). So
far, data linking viral integration to
recurrence and progression of BP
lesions are scarce.
Common treatment modalities of pe-
nile lesions such as BP include exci-
sion, circumcision, electrodessication,
laser ablation, cryotherapy, photo-
dynamic therapy, and local admini-
stration of 5-fluorouracil-containing
cream (Porter et al., 2002; Endo et al.,
2003). Recurrence rates, however, are
high and persistent lesions are regarded
as a precursor to malignancy (Gross and
Pfister, 2004). Therefore improvement
of therapeutic strategies is needed.
Imiquimod is a topical immune re-
sponse modifier inducing the produc-
tion of cytokines from monocytes and
macrophages, thus stimulating the
T-helper 1 response and most probably
also cytotoxic T-cell activation and a
B-cell response (Slade et al., 1998;
Suzuki et al., 2000). In addition, imiqui-
mod is believed to have antiangiogenic
activity (Li et al., 2005). Because imi-
quimod treatment has proven effective
in combating viral infections as well as
reducing (pre)malignant epithelial le-
sions (Hannuksela-Svahn et al. 2000;
Mackenzie-Wood et al., 2001; Petrow
et al., 2001), we applied this treatment
to two patients presenting with obstinate
BP lesions of which the presence and
physical status of HPV was determined
before and after treatment.
A 40-year-old male patient was
referred to our clinic with a 6-month
history of slightly pruritic penile pa-
pules. On clinical examination multiple
erythematous papules were seen on the
penile shaft, glans, and foreskin (Figure
1a). Histological examination revealed
full-thickness epithelial dysplasia, sup-
porting the clinical diagnosis of BP
(Figure 1b). PCR amplification on ex-
tracted DNA from this lesion demon-
strated infection with oncogenic HPV
(Figure 1c, lane 4), which turned out
to be type 16 after enzyme immuno-
assay typing (Van den Brule et al.,
2002). Fluorescent in situ hybridization
(FISH) analysis using a HPV-16-specific
probe showed diffuse staining of cell
nuclei indicating the presence of
episomal HPV in the lesion (Figure 1d)
(Hafkamp et al., 2003). Treatment with
imiquimod 5% cream for 16 weeks
was started. The cream was applied
once daily, three times a week. After
1 month a substantial improvement was
observed and after 16 weeks all skin
lesions had completely disappeared
(Figure 1f). Histological examination
of a skin biopsy tissue section 1 month
after imiquimod treatment showed in-
flammation and complete absence of
epithelial dysplasia (Figure 1g). This
finding coincided with disappearance
of the virus from the lesion, as revealed
by PCR (Figure 1c, lane 5) and FISH
analysis (Figure 1e). Nine months after
discontinuation of treatment no relapse
was observed. The authors declare that
the study received institutional ap-
proval, patients gave their informed
consent, and experiments were con-
ducted according to the principles for
Medical Research Involving Human
Subjects defined by the World Medical
Association the Declaration of Helsinki
Principles.
A 76-year-old male patient visited
our clinic because of itching erythema-
tous papules and plaques on the penile
glans and shaft. Histological examina-
tion of a biopsy revealed hyperkeratosis,
hyperplasia with cytonuclear atypia,
and mitoses (Figure 1h). Both clinical
presentation and histopathology sup-
ported the diagnosis of BP. PCR ampli-
fication on genomic DNA extracted
from this biopsy showed also infection
with HPV type 16 (Figure 1c, lane 7).
Interestingly, FISH analysis revealed
predominantly two punctate signals per
nucleus, indicating a pair of chromo-
somes with a single HPV16 integration
site (data not shown). First, treatment
with ablative CO2/Erbium laser was
performed to eliminate the lesions on
the glans and penile shaft. Six weeks
after this laser treatment the skin erup-
tion relapsed. We then started treatment
with imiquimod 5% cream. The lesions
reduced in size but there were still little
small plaques on the glans penis visible
after 16 weeks. One month after treat-
ment a new biopsy of a lesion was taken
and showed no dysplasia of the epithe-
lium (Figure 1i). However, molecular
analysis showed persistence of the viral
infection by PCR (Figure 1c, lane 8) and
FISH analysis (Figure 1j).
Our molecular examination of the
BP lesions before treatment revealed
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Figure 1. Histopathological and molecular analysis of BP lesions before and after treatment with imiquimod in (a–g) patient 1 and (c, h–j) patient 2.
(a) Macroscopic visualization of BP lesions on the penile shaft, glans, and foreskin before treatment. (b) Morphological visualization of a penile intraepithelial
neoplasia before treatment with atypia reaching the upper part of the epithelium and strong polymorphism of keratinocyte nuclei. (c) DNA agarose gel
electrophoresis after HPV-specific PCR, showing in lanes 1–2: positive control, lane 3: negative control, lane 4: presence of HPV in penile lesion of patient 1,
lane 5: no HPV in a skin biopsy after treatment, lane 6: 100 bp size marker, lanes 7–8: presence of HPV in penile lesions of patient 2 before and after treatment.
(d, e) FISH analysis of HPV16 on (d) a penile lesion before treatment showing diffuse nuclear staining indicating the presence of episomal HPV and
(e) a skin biopsy with no detectable HPV after treatment. (f, g) Absence of epidermal atypia by (f) macroscopic and (g) morphologic visualization of a skin biopsy
after 1 month of treatment. (h, i) Morphologic visualization of a BP lesion (h) before treatment, showing hyperplasia and keratosis of the epithelium with
cytonuclear atypia and mitoses, and after (i) 16 weeks of treatment, showing still some hyperplasia of the epidermis with little dysplasia and hyperkeratosis.
(j) FISH analysis of HPV16 on a penile lesion after treatment revealed two punctuate signals per nucleus indicating two sites with viral integration per cell.
Bar (b, g) ¼200 mm, (h, i)¼100 mm; (d, e) original magnification 250, and (j) original magnification400.
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the presence of HPV-16 in the episomal
form in the complete responder,
whereas viral integration was observed
in the partial responder. These results
indicate that triggering of the host
immune response by imiquimod is
especially efficient if oncogenic HPV
is replicating in the BP lesion and
integration in the cellular DNA has
not taken place. The various HPV-
expressed early and late proteins may
all contribute to effective T- and B-cell
responses (Jenson et al., 1991; Ho¨pfl
et al., 2000; Tindle, 2002; Van Poelge-
est et al., 2005). In case of viral
integration, however, which is asso-
ciated with a higher risk for malig-
nancy, the HPV genome is usually
disrupted within the E2 gene and also
E4, E5, and part of L2 are regularly
deleted (Zur Hausen, 2002). As a
consequence potential targets for T-cell
responses are eliminated. Moreover,
viral integration leads to high levels of
viral oncoproteins E6 and E7, which
have been shown to downregulate the
cell cycle regulatory proteins P53 and
phosphorylated Rb to maintain kerati-
nocytes in the cell cycle as well as to
effectively suppress cellular and inter-
feron-mediated immune responses in
addition (Tindle, 2002). In such cases,
vaccination of patients with a therapeu-
tic vaccine based on the HPV-encoded
oncoproteins E6 and E7 may be indi-
cated in the near future, because they
have shown encouraging results in
(pre)clinical settings (Albers et al.,
2005; Govan, 2005).
In conclusion, imiquimod treatment
provides a promising alternative ther-
apy for BP, particularly in cases in
which treatment is started whereas
HPV is replicating and present in the
episomal form. Our results suggest
that BP lesions showing viral integra-
tion into the cellular genome may
persist after imiquimod treatment.
After treatment discontinuation a con-
trol biopsy for HPV staining is recom-
mended to determine the efficacy of
imiquimod in the individual patient. A
higher proportion of cases will be
necessary to further substantiate our
findings.
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